0001582249
false
0001582249
2021-11-22
2021-11-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 22, 2021
RASNA
THERAPEUTICS, INC.
(Exact
Name of Registrant as Specified in Charter)
| Nevada |
|
333-191083 |
|
39-2080103 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification
No.) |
|
420 Lexington Avenue, Suite 2525, New York, NY |
|
10170 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: 646-396-4087
(Former
name or former address, if changed since last report)
Copies
to:
Jeffrey
Fessler, Esq.
Sheppard,
Mullin, Richter & Hampton LLP
30
Rockefeller Plaza
New
York, New York 10112
Telephone:
(212) 653-8700
Facsimile:
(212) 653-8701
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| |
|
|
|
|
Item
4.01 Change in Registrant’s Certifying Accountant
On
November 29, 2021, Rasna Therapeutics, Inc. (the “Company”) dismissed Marcum LLP (“Marcum”) as the Company’s
independent registered public accounting firm, effective immediately. On November 29, 2021, the Company appointed Mazars USA LLP (“Mazars”)
as the Company’s new independent registered public accounting firm effective as of November 29, 2021.
The
Audit Committee of the board of directors of the Company approved the dismissal of Marcum and the appointment of Mazars.
The
reports of Marcum on the Company’s financial statements for each of fiscal years ended September 30, 2020 and 2019 did not contain
an adverse opinion or a disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principle.
During
the fiscal years ended September 30, 2020 and 2019, and the subsequent interim period through November 29, 2021, there were no disagreements
(as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions) between the Company and Marcum on any
matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures which disagreements, if
not resolved to the satisfaction of Marcum would have caused Marcum to make reference thereto in their reports on the financial statements
for such years. The Company disclosed in its Form 10-K for the fiscal year ended September 30, 2020 and in subsequent 10-Q interim period
filings, that its internal control over financial reporting was not due to a lack of accounting resources and an ineffective control
environment.
The
Company provided Marcum with a copy of the disclosures it is making in this Current Report on Form 8-K and requested that Marcum furnish
the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements contained
herein. A copy of Marcum’s letter, dated November 30, 2021 is filed as Exhibit 16.1 to this Current Report on Form 8-K.
During
the fiscal year ended September 30, 2020 and the period from October 1, 2020 through November 29, 2021, neither the Company, nor anyone
acting on its behalf, consulted with Mazars regarding (i) the application of accounting principles to a specified transaction, either
completed or proposed, or the type of audit opinion that may be rendered on the Company’s financial statements, and Mazars did
not provide either a written report or oral advice to the Company that was an important factor considered by the Company in reaching
a decision as to the accounting, auditing or financial reporting issue, or (ii) any matter that was either the subject of a disagreement
(as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as described in Item 304(a)(1)(v)
of Regulation S-K).
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
The
exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
Date: November
30, 2021
| |
RASNA THERAPEUTICS, INC. |
| |
|
|
| |
By: |
/s/ Keeren
Shah |
| |
|
Name: |
Keeren Shah |
| |
|
Title: |
Chief FinancialOfficer |
2
